Reproductive BioMedicine Online
Volume 20, Issue 1 , Pages 42-47 , January 2010

Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors

Received 3 November 2008 ,Revised 3 December 2008 ,Accepted 24 September 2009.

References 

  1. Barnhart K, Osheroff J. We are overinterpreting the predictive value of serum follicle-stimulating hormone levels. Fertil. Steril. 1999;72:8–9
  2. Barreto Melo MA, Garrido N, Alvarez C, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil. Steril. 2009;91:148–156
  3. Cohen MA, Lindheim SR, Sauer MV. Donor age is paramount to success in oocyte donation. Hum. Reprod. 1999;14:2755–2758
  4. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil. Steril. 2002;77:141–146
  5. de Vet A, Laven JS, de Jong FH, et al. Antimullerian hormone serum levels: a putative marker for ovarian ageing. Fertil. Steril. 2002;77:357–362
  6. Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum. Reprod. 2006;21:2022–2026
  7. Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum. Reprod. 2002;17:118–123
  8. Faber BM, Mercan R, Hamacher P, et al. The impact of an egg donor’s age and her prior fertility on recipient pregnancy outcome. Fertil. Steril. 1997;68:370–372
  9. Fallat ME, Siow Y, Marra M, et al. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil. Steril. 1997;67:962–965
  10. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil. Steril. 2006;85:592–596
  11. Hazout A, Bouchard P, Seifer DB, et al. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or oestradiol. Fertil. Steril. 2004;82:1323–1329
  12. Hehenkamp WJ, Looman CW, Themmen AP, et al. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab. 2006;91:4057–4063
  13. Klein J, Sauer MV. Oocyte donation. Best Pract. Res. 2002;16:277–291
  14. Lee TH, Liu CH, Huang CC, et al. Serum anti-Mullerian hormone and oestradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 2008;23:160–167
  15. Letterie G, Marshall L, Angle M. The relationship of clinical response, oocyte number, and success in oocyte donor cycles. J. Assist. Reprod. Genet. 2005;22:115–117
  16. Nakhuda GS, Chu MC, Wang JG, et al. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil. Steril. 2006;85:1541–1543
  17. Nakhuda GS, Sauer MV, Wang JG, et al. Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reprod. BioMed. Online. 2007;14:450–454
  18. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Hum. Reprod. 2007;22:2414–2421
  19. Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril. 2002;77:468–471
  20. Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum. Reprod. 2006;21:159–163
  21. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007;134:196–201
  22. Tsepelidis S, Devreker F, Demeestere I, et al. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 2007;22:1837–1840
  23. van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 2002;17:3065–3071

 Dr Nakhuda is an assistant clinical professor in obstetrics and gynecology at Columbia University, where he completed both his residency in obstetrics and gynecology and his fellowship in reproductive endocrinology and infertility. His current research interests include assessment of ovarian reserve, HIV and assisted reproduction, and clinical embryology.

PII: S1472-6483(09)00152-7

doi: 10.1016/j.rbmo.2009.10.009

Reproductive BioMedicine Online
Volume 20, Issue 1 , Pages 42-47 , January 2010

Article Tools